The first FDA warning letter tied to artificial intelligence marks a turning point for GMP-regulated companies. AI already helps with automated quality reviews, predictive maintenance, complaint handling and CAPA management, and the letter makes clear that regulators want AI-supported processes validated, controlled, monitored and fully part of the quality management system (QMS).
This 60-minute webinar explains what the enforcement action means and how FDA's requirements for validation, data integrity, change control, risk management and oversight carry over to AI-driven systems and the decisions they support.
You'll also look at practical ways to bring AI into an existing quality system without losing compliance, from supplier qualification and algorithm validation to human oversight and deviation management, so you can prepare for inspections and protect patient safety and product quality.
WHY SHOULD YOU ATTEND?
AI use in regulated industries is growing fast, yet many companies are still unsure what FDA expects for validation, oversight, documentation and risk management. The first AI-related warning letter shows that regulators are looking closely at how AI-enabled systems are implemented and controlled.
This session gives QA, regulatory, validation, compliance, IT, operations, data integrity, risk and audit professionals, and leaders weighing AI adoption, practical guidance on the risks and the steps to keep quality systems inspection-ready.
AREA COVERED
- Overview of FDA's first AI-related warning letter
- Regulatory expectations for AI in GMP-regulated industries
- AI governance and integration with the quality system
- Computer system validation (CSV) and AI validation considerations
- Data integrity and audit trail requirements for AI systems
- Managing AI risks: bias, hallucinations and model drift
- Change control and lifecycle management for AI applications
- Human oversight and accountability in AI-assisted processes
- AI in CAPA, deviations, complaints and risk management
- Supplier qualification and oversight of third-party AI vendors
- Inspection readiness and documentation best practices
- Future trends in FDA regulation of AI
LEARNING OBJECTIVES
- Explain why FDA's first AI-related warning letter matters for GMP-regulated industries
- Identify FDA expectations for AI governance in GMP environments
- Describe how AI affects quality systems, validation and data integrity requirements
- Apply risk-based approaches to AI implementation and oversight
- Meet documentation and change control requirements for AI-enabled systems
- Evaluate AI risks such as bias, cybersecurity and automated decision-making
- Plan how to integrate AI into CAPA, deviation management and quality operations
- Prepare for regulatory inspections that involve AI-driven technologies
WHO WILL BENEFIT?
Professionals responsible for quality, compliance, validation, digital transformation, and regulatory oversight in regulated industries, including:
- Quality Assurance Managers and Directors
- Regulatory Affairs Professionals
- Validation and Computer System Validation (CSV) Specialists
- Compliance Officers
- Manufacturing and Operations Leaders
- IT and Digital Transformation Managers
- CAPA and Deviation Management Teams
- Data Integrity Specialists
- Risk Management Professionals
- Internal Auditors and Inspection Readiness Teams
- Executive Leadership evaluating AI adoption strategies.
AI use in regulated industries is growing fast, yet many companies are still unsure what FDA expects for validation, oversight, documentation and risk management. The first AI-related warning letter shows that regulators are looking closely at how AI-enabled systems are implemented and controlled.
This session gives QA, regulatory, validation, compliance, IT, operations, data integrity, risk and audit professionals, and leaders weighing AI adoption, practical guidance on the risks and the steps to keep quality systems inspection-ready.
- Overview of FDA's first AI-related warning letter
- Regulatory expectations for AI in GMP-regulated industries
- AI governance and integration with the quality system
- Computer system validation (CSV) and AI validation considerations
- Data integrity and audit trail requirements for AI systems
- Managing AI risks: bias, hallucinations and model drift
- Change control and lifecycle management for AI applications
- Human oversight and accountability in AI-assisted processes
- AI in CAPA, deviations, complaints and risk management
- Supplier qualification and oversight of third-party AI vendors
- Inspection readiness and documentation best practices
- Future trends in FDA regulation of AI
- Explain why FDA's first AI-related warning letter matters for GMP-regulated industries
- Identify FDA expectations for AI governance in GMP environments
- Describe how AI affects quality systems, validation and data integrity requirements
- Apply risk-based approaches to AI implementation and oversight
- Meet documentation and change control requirements for AI-enabled systems
- Evaluate AI risks such as bias, cybersecurity and automated decision-making
- Plan how to integrate AI into CAPA, deviation management and quality operations
- Prepare for regulatory inspections that involve AI-driven technologies
Professionals responsible for quality, compliance, validation, digital transformation, and regulatory oversight in regulated industries, including:
- Quality Assurance Managers and Directors
- Regulatory Affairs Professionals
- Validation and Computer System Validation (CSV) Specialists
- Compliance Officers
- Manufacturing and Operations Leaders
- IT and Digital Transformation Managers
- CAPA and Deviation Management Teams
- Data Integrity Specialists
- Risk Management Professionals
- Internal Auditors and Inspection Readiness Teams
- Executive Leadership evaluating AI adoption strategies.
